100 Summer Street
Suite 2300
Boston, MA 02110
United States
617 621 7722
https://www.ironwoodpharma.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 267
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Ms. Julie H. McHugh | Executive Chairman of the Board | 95k | N/D | 1964 |
Mr. Thomas A. McCourt | CEO & Director | 1.42M | N/D | 1957 |
Mr. John Minardo | Senior VP, Chief Legal Officer & Secretary | 675.88k | N/D | 1977 |
Dr. Michael Shetzline M.D., Ph.D. | Chief Medical Officer, Senior VP and Head of Research & Drug Development | 837.74k | N/D | 1960 |
Mr. Ronald Silver | Corporate Controller & Principal Accounting Officer | N/D | N/D | 1983 |
Mr. Marcel Moulaison | Vice President of Technical Operations | N/D | N/D | N/D |
Greg Martini | Vice President of Strategic Finance & Investor Relations | N/D | N/D | N/D |
Ms. Beth Calitri | Head of Corporate Communications & Media Relations | N/D | N/D | N/D |
Mr. Mike Nanfito | Vice President of Sales & Sales Excellence | N/D | N/D | N/D |
Mr. Andrew Davis | Senior VP & Chief Business Officer | N/D | N/D | 1987 |
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
La calificación ISS Governance QuickScore de Ironwood Pharmaceuticals, Inc. a partir del 1 de abril de 2024 es 3. Las puntuaciones principales son Auditoría: 6; Junta: 3; Derechos del accionista: 6; Compensación: 1.